Constance M. Mobley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Constance M. Mobley has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
- Rafik Mark Ghobrial
Department of Surgery, Houston Methodist Hospital, Houston, TX, USA
10 shared publications - Ahmed Osama Gaber
Department of Surgery, Houston Methodist Hospital, Houston, TX, USA
8 shared publications - Ashish Saharia
Department of Surgery, Houston Methodist Hospital, Houston, TX
8 shared publications - David W. Victor
JC Walter Jr Transplant Center, Houston Methodist Hospital, Houston, TX
7 shared publications - Ashton A. Connor
Department of Surgery, Houston Methodist Hospital, Houston, TX, USA
6 shared publications - Mark J. Hobeika
Department of Surgery, Houston Methodist Hospital, Houston, TX
6 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
Pretransplant recurrent liver cancer prediction score (p-RELAPSE) to risk stratify hepatocellular carcinoma patients undergoing liver transplantation: validation in an international multicenter retrospective cohort
Background: Selection of patients with hepatocellular carcinoma (HCC) for liver transplantation (LT) increasingly integrates dynamic tumor biology alongside morphometric criteria. Methods: We developed and externally validated the pre-transplant REcurrent Liver cAncer Prediction ScorE (p-RELAPSE) to predict post-LT recurrence using two retrospective cohorts. Post-LT outcomes of 4420 HCC patients undergoing LT in the US Multicenter HCC Transplant Consortium (UMHTC) were analyzed to derive p-RELAPSE using a competing risks multivariable model, with external validation in 1736 HCC LT recipients from the European Hepatocellular Cancer Liver Transplant (EurHeCaLT) group. Results: The UMHTC training ( n = 2893), internal validation ( n = 1527), and EurHeCaLT ( n = 1736) cohorts showed comparable 5-year overall survival (69.4–71.0%), recurrence-free survival (66.2–66.3%), and recurrence incidence (12.6–14.4%; all P > 0.05). p-RELAPSE incorporated Milan criteria (MC) status, downstaging, maximum tumor diameter, dynamic alpha-fetoprotein (AFP) response, and waitlist time. The model stratified recurrence risk even within MC patients. In EurHeCaLT, p-RELAPSE achieved a C-statistic of 0.69, outperforming MC, French AFP, Up-to-7, pre-MORAL, and New York/California models ( P < 0.05). Conclusions: By integrating AFP dynamics and waitlist time, p-RELAPSE refines post-LT recurrence risk stratification, identifying MC patients unlikely to benefit from LT and non-MC patients with favorable outcomes. This externally validated model provides a robust framework for individualized pre-LT decision-making in HCC candidates.
- 11 November 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
Open AccessPretransplant recurrent liver cancer prediction score (p-RELAPSE) to risk stratify hepatocellular carcinoma patients undergoing liver transplantation: validation in an international multicenter retrospective cohort
Background: Selection of patients with hepatocellular carcinoma (HCC) for liver transplantation (LT) increasingly integrates dynamic tumor biology alongside morphometric criteria. Methods: We developed and externally validated the pre-transplant REcurrent Liver cAncer Prediction ScorE (p-RELAPSE) to predict post-LT recurrence using two retrospective cohorts. Post-LT outcomes of 4420 HCC patients undergoing LT in the US Multicenter HCC Transplant Consortium (UMHTC) were analyzed to derive p-RELAPSE using a competing risks multivariable model, with external validation in 1736 HCC LT recipients from the European Hepatocellular Cancer Liver Transplant (EurHeCaLT) group. Results: The UMHTC training ( n = 2893), internal validation ( n = 1527), and EurHeCaLT ( n = 1736) cohorts showed comparable 5-year overall survival (69.4–71.0%), recurrence-free survival (66.2–66.3%), and recurrence incidence (12.6–14.4%; all P > 0.05). p-RELAPSE incorporated Milan criteria (MC) status, downstaging, maximum tumor diameter, dynamic alpha-fetoprotein (AFP) response, and waitlist time. The model stratified recurrence risk even within MC patients. In EurHeCaLT, p-RELAPSE achieved a C-statistic of 0.69, outperforming MC, French AFP, Up-to-7, pre-MORAL, and New York/California models ( P < 0.05). Conclusions: By integrating AFP dynamics and waitlist time, p-RELAPSE refines post-LT recurrence risk stratification, identifying MC patients unlikely to benefit from LT and non-MC patients with favorable outcomes. This externally validated model provides a robust framework for individualized pre-LT decision-making in HCC candidates.
- 14 October 2026
- Published by Springer Nature in Surgical Endoscopy
- p. 1-10
Robotic liver resection learning curves stratified by IWATE criteria
- 14 October 2026
- Published by Springer Nature in Surgical Endoscopy
- p. 1-10
Robotic liver resection learning curves stratified by IWATE criteria
- 10 June 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (7) , e70176
Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation
Background: Voriconazole is a triazole antifungal, primarily metabolized by the liver, and poses a dosing challenge in patients with liver impairment. Although the manufacturer recommends a maintenance dose reduction for mild‐to‐moderate hepatic dysfunction, no standardized recommendations exist for severe liver impairment. Prior evidence suggests a need for significant dose reduction in the setting of severe liver failure; however, there is limited data on empirical dosing in patients undergoing orthotopic liver transplant (OLT) evaluation and surgery. Methods: This is a single‐center, retrospective cohort study assessing voriconazole dosing and therapeutic drug monitoring (TDM) in patients with advanced cirrhosis who received voriconazole during urgent OLT evaluation and/or surgery. Patients were included if voriconazole trough concentrations were collected at least 7 days after therapy initiation pre‐OLT or at least 5 days post‐OLT. The target therapeutic range was defined as 1–4 mcg/mL. The primary outcome was the distribution of voriconazole trough concentrations in the pre‐ and post‐transplant cohorts. Results: The pre‐OLT cohort comprised 76 patients with 124 concentrations, and the post‐OLT cohort comprised 36 patients with 71 concentrations. As anticipated, the pre‐OLT group exhibited more abnormal liver enzymes and a high median Model for End‐Stage Liver Disease (MELD) score of 35 (Interquartile Range (IQR) 29.5–40). In the pre‐OLT setting, doses less than 2 mg/kg/dose were more likely associated with therapeutic voriconazole concentrations. Supratherapeutic concentrations were observed in 41 patients (average dose of 2.4 mg/kg/dose), of which five patients required therapy interruption. In the post‐OLT group, only 23 of 71 concentrations fell within the therapeutic range, with an average dose of 2.8 mg/kg/dose. Conclusion: We found that empiric voriconazole dosing in patients with advanced cirrhosis undergoing OLT evaluation should not exceed 2 mg/kg/dose initially to mitigate the risk of drug accumulation and potential toxicity. In post‐OLT patients, it is reasonable to consider reverting to standard manufacturer‐recommended dosing. Given the pharmacokinetic variability observed, TDM is essential for effective and safe management in this high‐risk patient population.
- 10 June 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (7) , e70176
Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation
Background: Voriconazole is a triazole antifungal, primarily metabolized by the liver, and poses a dosing challenge in patients with liver impairment. Although the manufacturer recommends a maintenance dose reduction for mild‐to‐moderate hepatic dysfunction, no standardized recommendations exist for severe liver impairment. Prior evidence suggests a need for significant dose reduction in the setting of severe liver failure; however, there is limited data on empirical dosing in patients undergoing orthotopic liver transplant (OLT) evaluation and surgery. Methods: This is a single‐center, retrospective cohort study assessing voriconazole dosing and therapeutic drug monitoring (TDM) in patients with advanced cirrhosis who received voriconazole during urgent OLT evaluation and/or surgery. Patients were included if voriconazole trough concentrations were collected at least 7 days after therapy initiation pre‐OLT or at least 5 days post‐OLT. The target therapeutic range was defined as 1–4 mcg/mL. The primary outcome was the distribution of voriconazole trough concentrations in the pre‐ and post‐transplant cohorts. Results: The pre‐OLT cohort comprised 76 patients with 124 concentrations, and the post‐OLT cohort comprised 36 patients with 71 concentrations. As anticipated, the pre‐OLT group exhibited more abnormal liver enzymes and a high median Model for End‐Stage Liver Disease (MELD) score of 35 (Interquartile Range (IQR) 29.5–40). In the pre‐OLT setting, doses less than 2 mg/kg/dose were more likely associated with therapeutic voriconazole concentrations. Supratherapeutic concentrations were observed in 41 patients (average dose of 2.4 mg/kg/dose), of which five patients required therapy interruption. In the post‐OLT group, only 23 of 71 concentrations fell within the therapeutic range, with an average dose of 2.8 mg/kg/dose. Conclusion: We found that empiric voriconazole dosing in patients with advanced cirrhosis undergoing OLT evaluation should not exceed 2 mg/kg/dose initially to mitigate the risk of drug accumulation and potential toxicity. In post‐OLT patients, it is reasonable to consider reverting to standard manufacturer‐recommended dosing. Given the pharmacokinetic variability observed, TDM is essential for effective and safe management in this high‐risk patient population.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (3) , e2500691
Molecular Profiling of Cholangiocarcinoma Predicts Outcomes Post-Liver Transplantation
PURPOSE: Cholangiocarcinoma (CCA) has rising incidence and mortality rates. Liver transplantation (LT) offers good outcomes. Tumor molecular profiling may inform peri-LT treatment. MATERIALS AND METHODS: Patients with CCA who underwent LT at a single center between 2014 and 2021 were identified retrospectively. Next-generation sequencing (277 genes) was performed on 28 CCAs from 18 patients, including five perihilar and 24 intrahepatic tumors. RESULTS: Mutations were reported in 45 genes, most frequently IDH1 (5 patients), BAP1 (5), and TP53 (4). BAP1 was associated with neoadjuvant treatment response. Altered genes were organized into five pathways, namely: kinase-RAS (11 patients), TP53 (9), epigenetic (8), SWI-SNF (7) and RB-cell cycle (4). Both TP53 and RB-cell cycle pathway alterations were prognostic. Tumors were clustered into three groups, named here as cell cycle (seven patients), genomic instability (6), and cell survival (5). The latter had no post-transplant deaths. In 18 serially sequenced tumors from eight patients, mutational heterogeneity over time was quantified by Jaccard Index. This reflected both external selection pressures by systemic therapies and intrinsic tumor biology, being the lowest in cell survival tumors. Pathway- and subtype-level changes were rare. CONCLUSION: In this LT cohort, CCA molecular profiling informed prognosis and treatment response. Heterogeneity may depend on early tumorigenesis disruptions, potentially explaining outcome differences.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (3) , e2500691
Molecular Profiling of Cholangiocarcinoma Predicts Outcomes Post-Liver Transplantation
PURPOSE: Cholangiocarcinoma (CCA) has rising incidence and mortality rates. Liver transplantation (LT) offers good outcomes. Tumor molecular profiling may inform peri-LT treatment. MATERIALS AND METHODS: Patients with CCA who underwent LT at a single center between 2014 and 2021 were identified retrospectively. Next-generation sequencing (277 genes) was performed on 28 CCAs from 18 patients, including five perihilar and 24 intrahepatic tumors. RESULTS: Mutations were reported in 45 genes, most frequently IDH1 (5 patients), BAP1 (5), and TP53 (4). BAP1 was associated with neoadjuvant treatment response. Altered genes were organized into five pathways, namely: kinase-RAS (11 patients), TP53 (9), epigenetic (8), SWI-SNF (7) and RB-cell cycle (4). Both TP53 and RB-cell cycle pathway alterations were prognostic. Tumors were clustered into three groups, named here as cell cycle (seven patients), genomic instability (6), and cell survival (5). The latter had no post-transplant deaths. In 18 serially sequenced tumors from eight patients, mutational heterogeneity over time was quantified by Jaccard Index. This reflected both external selection pressures by systemic therapies and intrinsic tumor biology, being the lowest in cell survival tumors. Pathway- and subtype-level changes were rare. CONCLUSION: In this LT cohort, CCA molecular profiling informed prognosis and treatment response. Heterogeneity may depend on early tumorigenesis disruptions, potentially explaining outcome differences.
- Open Access
- 7 February 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (3) , e1760
Neoadjuvant Multiagent Systemic Therapy Approach to Liver Transplantation for Perihilar Cholangiocarcinoma
Background.: Perihilar cholangiocarcinoma (phCCA) has excellent outcomes following liver transplantation (LT). Neoadjuvant radiation-based locoregional therapy is standard-of-care. Gemcitabine and cisplatin (gem/cis) combination systemic therapies have improved outcomes in advanced settings, but their efficacy pre-LT has not been studied. Methods.: We review our experience following neoadjuvant gem/cis alone versus radiation-based approaches. Patients with phCCA undergoing LT at a single center between January 2008 and February 2023 were identified retrospectively. Neoadjuvant therapy was categorized as gem/cis systemic therapy (ST) alone, or any ST and radiotherapy (RT). Outcomes were posttransplant overall survival (OS), recurrence-free survival (RFS), waitlist time, and pathologic tumor response. Results.: During study period, 27 phCCA patients underwent LT. One patient decompensated with neoadjuvant therapy and was excluded. Median age was 61 y (interquartile range, 53–68 y) and 14 (54%) were male. Of 26 patients, 12 (46%) received ST and 14 (54%) RT. Six RT patients received gem/cis ST. Median waitlist time was 199 d (interquartile range, 98–405 d) and did not differ by neoadjuvant regimen. Explanted tumors were predominantly T1 stage, without lymphovascular invasion or nodal involvement. Neither pathologic features nor percent tumor necrosis differed by regimen. OS probabilities at 1 and 3 y were 84% and 55% for the cohort. There was no significant difference in OS and RFS when stratified by regimen. Conclusions.: Post-LT OS, RFS, waitlist time, and tumor response were similar in the 2 groups. Patients with phCCA who do not undergo RT may still be considered for LT under appropriate institution-based protocols that adhere to other established criteria.
- 7 February 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (3) , e1760
Open AccessNeoadjuvant Multiagent Systemic Therapy Approach to Liver Transplantation for Perihilar Cholangiocarcinoma
Background.: Perihilar cholangiocarcinoma (phCCA) has excellent outcomes following liver transplantation (LT). Neoadjuvant radiation-based locoregional therapy is standard-of-care. Gemcitabine and cisplatin (gem/cis) combination systemic therapies have improved outcomes in advanced settings, but their efficacy pre-LT has not been studied. Methods.: We review our experience following neoadjuvant gem/cis alone versus radiation-based approaches. Patients with phCCA undergoing LT at a single center between January 2008 and February 2023 were identified retrospectively. Neoadjuvant therapy was categorized as gem/cis systemic therapy (ST) alone, or any ST and radiotherapy (RT). Outcomes were posttransplant overall survival (OS), recurrence-free survival (RFS), waitlist time, and pathologic tumor response. Results.: During study period, 27 phCCA patients underwent LT. One patient decompensated with neoadjuvant therapy and was excluded. Median age was 61 y (interquartile range, 53–68 y) and 14 (54%) were male. Of 26 patients, 12 (46%) received ST and 14 (54%) RT. Six RT patients received gem/cis ST. Median waitlist time was 199 d (interquartile range, 98–405 d) and did not differ by neoadjuvant regimen. Explanted tumors were predominantly T1 stage, without lymphovascular invasion or nodal involvement. Neither pathologic features nor percent tumor necrosis differed by regimen. OS probabilities at 1 and 3 y were 84% and 55% for the cohort. There was no significant difference in OS and RFS when stratified by regimen. Conclusions.: Post-LT OS, RFS, waitlist time, and tumor response were similar in the 2 groups. Patients with phCCA who do not undergo RT may still be considered for LT under appropriate institution-based protocols that adhere to other established criteria.
- Open Access
- 23 January 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (2) , e1746
Sorafenib as Adjuvant Therapy Post–Liver Transplant: A Single-center Experience
Background.: Hepatocellular carcinoma (HCC) has a rising incidence and mortality in North America. Liver transplantation (LT) with adjunctive therapies offers excellent outcomes. However, HCC recurrences are associated with high mortality. We investigate whether adjuvant systemic therapy can reduce recurrence, as shown with other malignancies. Methods.: Medical records of patients undergoing LT for HCC at a single center between January 2016 and December 2022 were retrospectively reviewed. Patients were stratified into 3 groups: (1) recipients of adjuvant sorafenib, (2) nonrecipients at high recurrence risk, and (3) nonrecipients at low risk by explant pathology features. The outcomes were overall survival (OS) and recurrence-free survival (RFS). Adjuvant sorafenib recipients were also propensity score matched 1:2 to nonadjuvant recipients based on recurrence risk features. Results.: During the study period, 273 patients with HCC underwent LT and 16 (5.9%) received adjuvant sorafenib therapy. Adjuvant sorafenib recipients were demographically similar to nonrecipients and, on explant pathology, had greater tumor burden, lymphovascular invasion, and poorer differentiation (all P < 0.001). Adverse events were observed in 12 adjuvant sorafenib recipients (75%). OS was similar among the 3 groups (P = 0.2), and adjuvant sorafenib was not associated with OS in multivariable analysis (hazard ratio, 1.31; 95% confidence interval, 0.45-3.78; P = 0.62). RFS was significantly lower in sorafenib patients (hazard ratio, 6.99; 95% confidence interval, 2.12-23.05; P = 0.001). Following propensity matching, adjuvant sorafenib use was not associated with either OS (P = 0.24) or RFS rates (P = 0.65). Conclusions.: In this single-center analysis, adjuvant sorafenib was not associated with OS. Recipients were observed to have shorter RFS, likely due to the increased prevalence of high-risk features, and sorafenib use was associated with high frequencies of adverse events.
- 23 January 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (2) , e1746
Open AccessSorafenib as Adjuvant Therapy Post–Liver Transplant: A Single-center Experience
Background.: Hepatocellular carcinoma (HCC) has a rising incidence and mortality in North America. Liver transplantation (LT) with adjunctive therapies offers excellent outcomes. However, HCC recurrences are associated with high mortality. We investigate whether adjuvant systemic therapy can reduce recurrence, as shown with other malignancies. Methods.: Medical records of patients undergoing LT for HCC at a single center between January 2016 and December 2022 were retrospectively reviewed. Patients were stratified into 3 groups: (1) recipients of adjuvant sorafenib, (2) nonrecipients at high recurrence risk, and (3) nonrecipients at low risk by explant pathology features. The outcomes were overall survival (OS) and recurrence-free survival (RFS). Adjuvant sorafenib recipients were also propensity score matched 1:2 to nonadjuvant recipients based on recurrence risk features. Results.: During the study period, 273 patients with HCC underwent LT and 16 (5.9%) received adjuvant sorafenib therapy. Adjuvant sorafenib recipients were demographically similar to nonrecipients and, on explant pathology, had greater tumor burden, lymphovascular invasion, and poorer differentiation (all P < 0.001). Adverse events were observed in 12 adjuvant sorafenib recipients (75%). OS was similar among the 3 groups (P = 0.2), and adjuvant sorafenib was not associated with OS in multivariable analysis (hazard ratio, 1.31; 95% confidence interval, 0.45-3.78; P = 0.62). RFS was significantly lower in sorafenib patients (hazard ratio, 6.99; 95% confidence interval, 2.12-23.05; P = 0.001). Following propensity matching, adjuvant sorafenib use was not associated with either OS (P = 0.24) or RFS rates (P = 0.65). Conclusions.: In this single-center analysis, adjuvant sorafenib was not associated with OS. Recipients were observed to have shorter RFS, likely due to the increased prevalence of high-risk features, and sorafenib use was associated with high frequencies of adverse events.
- 16 July 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (5) , e14331
Outcomes in solid organ transplant recipients receiving organs from a donor with Fusarium solani species complex meningitis
Background: Five organs (heart, right lung, liver, right, and left kidneys) from a deceased patient were transplanted into five recipients in four US states; the deceased patient was identified as part of a healthcare‐associated fungal meningitis outbreak among patients who underwent epidural anesthesia in Matamoros, Mexico. Methods: After transplant surgeries occurred, Fusarium solani species complex, a fungal pathogen with a high case‐mortality rate, was identified in cerebrospinal fluid from the organ donor by metagenomic next‐generation sequencing (mNGS) and fungal‐specific polymerase chain reaction and in plasma by mNGS. Results: Four of five transplant recipients received recommended voriconazole prophylaxis; four were monitored weekly by serum (1‐3)‐β‐ d ‐glucan testing. All five were monitored for signs of infection for at least 3 months following transplantation. The liver recipient had graft failure, which was attributed to an etiology unrelated to fungal infection. No fungal DNA was identified in sections of the explanted liver, suggesting that F. solani species complex did not contribute to graft failure. The remaining recipients experienced no signs or symptoms suggestive of fusariosis. Conclusion: Antifungal prophylaxis may be useful in preventing donor‐derived infections in recipients of organs from donors that are found to have Fusarium meningitis. image
- 16 July 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (5) , e14331
Outcomes in solid organ transplant recipients receiving organs from a donor with Fusarium solani species complex meningitis
Background: Five organs (heart, right lung, liver, right, and left kidneys) from a deceased patient were transplanted into five recipients in four US states; the deceased patient was identified as part of a healthcare‐associated fungal meningitis outbreak among patients who underwent epidural anesthesia in Matamoros, Mexico. Methods: After transplant surgeries occurred, Fusarium solani species complex, a fungal pathogen with a high case‐mortality rate, was identified in cerebrospinal fluid from the organ donor by metagenomic next‐generation sequencing (mNGS) and fungal‐specific polymerase chain reaction and in plasma by mNGS. Results: Four of five transplant recipients received recommended voriconazole prophylaxis; four were monitored weekly by serum (1‐3)‐β‐ d ‐glucan testing. All five were monitored for signs of infection for at least 3 months following transplantation. The liver recipient had graft failure, which was attributed to an etiology unrelated to fungal infection. No fungal DNA was identified in sections of the explanted liver, suggesting that F. solani species complex did not contribute to graft failure. The remaining recipients experienced no signs or symptoms suggestive of fusariosis. Conclusion: Antifungal prophylaxis may be useful in preventing donor‐derived infections in recipients of organs from donors that are found to have Fusarium meningitis. image
- Open Access
- 7 March 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (4) , e1590
Single-center Outcomes After Liver Transplantation With SARS-CoV-2–Positive Donors: An Argument for Increased Utilization
Background.: The COVID-19 pandemic has led to an increase in SARS-CoV-2–test positive potential organ donors. The benefits of life-saving liver transplantation (LT) must be balanced against the potential risk of donor-derived viral transmission. Although emerging evidence suggests that the use of COVID-19–positive donor organs may be safe, granular series thoroughly evaluating safety are still needed. Results of 29 consecutive LTs from COVID-19–positive donors at a single center are presented here. Methods.: A retrospective cohort study of LT recipients between April 2020 and December 2022 was conducted. Differences between recipients of COVID-19–positive (n = 29 total; 25 index, 4 redo) and COVID-19–negative (n = 472 total; 454 index, 18 redo) deceased donor liver grafts were compared. Results.: COVID-19–positive donors were significantly younger (P = 0.04) and had lower kidney donor profile indices (P = 0.04) than COVID-19–negative donors. Recipients of COVID-19–positive donor grafts were older (P = 0.04) but otherwise similar to recipients of negative donors. Donor SARS-CoV-2 infection status was not associated with a overall survival of recipients (hazard ratio, 1.11; 95% confidence interval, 0.24-5.04; P = 0.89). There were 3 deaths among recipients of liver grafts from COVID-19–positive donors. No death seemed virally mediated because there was no qualitative association with peri-LT antispike antibody titers, post-LT prophylaxis, or SARS-CoV-2 variants. Conclusions.: The utilization of liver grafts from COVID-19–positive donors was not associated with a decreased overall survival of recipients. There was no suggestion of viral transmission from donor to recipient. The results from this large single-center study suggest that COVID-19–positive donors may be used safely to expand the deceased donor pool.
- 7 March 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (4) , e1590
Open AccessSingle-center Outcomes After Liver Transplantation With SARS-CoV-2–Positive Donors: An Argument for Increased Utilization
Background.: The COVID-19 pandemic has led to an increase in SARS-CoV-2–test positive potential organ donors. The benefits of life-saving liver transplantation (LT) must be balanced against the potential risk of donor-derived viral transmission. Although emerging evidence suggests that the use of COVID-19–positive donor organs may be safe, granular series thoroughly evaluating safety are still needed. Results of 29 consecutive LTs from COVID-19–positive donors at a single center are presented here. Methods.: A retrospective cohort study of LT recipients between April 2020 and December 2022 was conducted. Differences between recipients of COVID-19–positive (n = 29 total; 25 index, 4 redo) and COVID-19–negative (n = 472 total; 454 index, 18 redo) deceased donor liver grafts were compared. Results.: COVID-19–positive donors were significantly younger (P = 0.04) and had lower kidney donor profile indices (P = 0.04) than COVID-19–negative donors. Recipients of COVID-19–positive donor grafts were older (P = 0.04) but otherwise similar to recipients of negative donors. Donor SARS-CoV-2 infection status was not associated with a overall survival of recipients (hazard ratio, 1.11; 95% confidence interval, 0.24-5.04; P = 0.89). There were 3 deaths among recipients of liver grafts from COVID-19–positive donors. No death seemed virally mediated because there was no qualitative association with peri-LT antispike antibody titers, post-LT prophylaxis, or SARS-CoV-2 variants. Conclusions.: The utilization of liver grafts from COVID-19–positive donors was not associated with a decreased overall survival of recipients. There was no suggestion of viral transmission from donor to recipient. The results from this large single-center study suggest that COVID-19–positive donors may be used safely to expand the deceased donor pool.
- 10 April 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 29 (7) , 683-697
Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium
HCC recurrence following liver transplantation (LT) is highly morbid and occurs despite strict patient selection criteria. Individualized prediction of post-LT HCC recurrence risk remains an important need. Clinico-radiologic and pathologic data of 4981 patients with HCC undergoing LT from the US Multicenter HCC Transplant Consortium (UMHTC) were analyzed to develop a REcurrent Liver cAncer Prediction ScorE (RELAPSE). Multivariable Fine and Gray competing risk analysis and machine learning algorithms (Random Survival Forest and Classification and Regression Tree models) identified variables to model HCC recurrence. RELAPSE was externally validated in 1160 HCC LT recipients from the European Hepatocellular Cancer Liver Transplant study group. Of 4981 UMHTC patients with HCC undergoing LT, 71.9% were within Milan criteria, 16.1% were initially beyond Milan criteria with 9.4% downstaged before LT, and 12.0% had incidental HCC on explant pathology. Overall and recurrence-free survival at 1, 3, and 5 years was 89.7%, 78.6%, and 69.8% and 86.8%, 74.9%, and 66.7%, respectively, with a 5-year incidence of HCC recurrence of 12.5% (median 16 months) and non-HCC mortality of 20.8%. A multivariable model identified maximum alpha-fetoprotein (HR = 1.35 per-log SD, 95% CI,1.22–1.50, p < 0.001), neutrophil-lymphocyte ratio (HR = 1.16 per-log SD, 95% CI,1.04–1.28, p < 0.006), pathologic maximum tumor diameter (HR = 1.53 per-log SD, 95% CI, 1.35–1.73, p < 0.001), microvascular (HR = 2.37, 95%–CI, 1.87–2.99, p < 0.001) and macrovascular (HR = 3.38, 95% CI, 2.41–4.75, p < 0.001) invasion, and tumor differentiation (moderate HR = 1.75, 95% CI, 1.29–2.37, p < 0.001; poor HR = 2.62, 95% CI, 1.54–3.32, p < 0.001) as independent variables predicting post-LT HCC recurrence (C-statistic = 0.78). Machine learning algorithms incorporating additional covariates improved prediction of recurrence (Random Survival Forest C-statistic = 0.81). Despite significant differences in European Hepatocellular Cancer Liver Transplant recipient radiologic, treatment, and pathologic characteristics, external validation of RELAPSE demonstrated consistent 2- and 5-year recurrence risk discrimination (AUCs 0.77 and 0.75, respectively). We developed and externally validated a RELAPSE score that accurately discriminates post-LT HCC recurrence risk and may allow for individualized post-LT surveillance, immunosuppression modification, and selection of high-risk patients for adjuvant therapies.
- 10 April 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 29 (7) , 683-697
Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium
HCC recurrence following liver transplantation (LT) is highly morbid and occurs despite strict patient selection criteria. Individualized prediction of post-LT HCC recurrence risk remains an important need. Clinico-radiologic and pathologic data of 4981 patients with HCC undergoing LT from the US Multicenter HCC Transplant Consortium (UMHTC) were analyzed to develop a REcurrent Liver cAncer Prediction ScorE (RELAPSE). Multivariable Fine and Gray competing risk analysis and machine learning algorithms (Random Survival Forest and Classification and Regression Tree models) identified variables to model HCC recurrence. RELAPSE was externally validated in 1160 HCC LT recipients from the European Hepatocellular Cancer Liver Transplant study group. Of 4981 UMHTC patients with HCC undergoing LT, 71.9% were within Milan criteria, 16.1% were initially beyond Milan criteria with 9.4% downstaged before LT, and 12.0% had incidental HCC on explant pathology. Overall and recurrence-free survival at 1, 3, and 5 years was 89.7%, 78.6%, and 69.8% and 86.8%, 74.9%, and 66.7%, respectively, with a 5-year incidence of HCC recurrence of 12.5% (median 16 months) and non-HCC mortality of 20.8%. A multivariable model identified maximum alpha-fetoprotein (HR = 1.35 per-log SD, 95% CI,1.22–1.50, p < 0.001), neutrophil-lymphocyte ratio (HR = 1.16 per-log SD, 95% CI,1.04–1.28, p < 0.006), pathologic maximum tumor diameter (HR = 1.53 per-log SD, 95% CI, 1.35–1.73, p < 0.001), microvascular (HR = 2.37, 95%–CI, 1.87–2.99, p < 0.001) and macrovascular (HR = 3.38, 95% CI, 2.41–4.75, p < 0.001) invasion, and tumor differentiation (moderate HR = 1.75, 95% CI, 1.29–2.37, p < 0.001; poor HR = 2.62, 95% CI, 1.54–3.32, p < 0.001) as independent variables predicting post-LT HCC recurrence (C-statistic = 0.78). Machine learning algorithms incorporating additional covariates improved prediction of recurrence (Random Survival Forest C-statistic = 0.81). Despite significant differences in European Hepatocellular Cancer Liver Transplant recipient radiologic, treatment, and pathologic characteristics, external validation of RELAPSE demonstrated consistent 2- and 5-year recurrence risk discrimination (AUCs 0.77 and 0.75, respectively). We developed and externally validated a RELAPSE score that accurately discriminates post-LT HCC recurrence risk and may allow for individualized post-LT surveillance, immunosuppression modification, and selection of high-risk patients for adjuvant therapies.
- 1 February 2022
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 20 (2) , 409-418.e5
Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis
- 1 February 2022
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 20 (2) , 409-418.e5
Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis